18:51 , May 15, 2019 |  BC Extra  |  Company News

Vertex moving into protein degradation with Kymera collaboration

In another move to expand its suite of modalities to address serious diseases, Vertex has partnered with Kymera to develop targeted small molecule protein degraders under a four-year deal. Kymera Therapeutics LLC (Cambridge, Mass.) will...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
15:54 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Kymera raises $65M series B

Protein degradation company Kymera Therapeutics LLC (Cambridge, Mass.) closed an untranched $65 million series B round on Nov. 13 to bring its lead program into the clinic. Kymera is developing heterobifunctional molecules that bind to...
16:25 , Nov 13, 2018 |  BioCentury  |  Finance

Kymera’s degradation toolbox

As the protein degradation space continues to gain traction, Kymera Therapeutics LLC has attracted interest from investors to the tune of $65 million to bring its first program to the clinic. 6 Dimensions Capital, Bessemer...
12:03 , Nov 13, 2018 |  BC Extra  |  Financial News

Kymera raises $65M series B

Protein degradation company Kymera Therapeutics LLC (Cambridge, Mass.) closed an untranched $65 million series B round to bring its lead program into the clinic. Kymera is developing heterobifunctional molecules that bind to both an E3...
04:47 , Nov 9, 2018 |  BC Innovations  |  Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
22:59 , Nov 1, 2018 |  BC Extra  |  Tools & Techniques

Selective degradation could be on horizon for imids

A Science study published Thursday suggests selective degradation of hard-to-drug zinc finger transcription factors could be achieved by modifying thalidomide or its analogs, collectively called imids. The results put forth a recipe to predict which...
00:38 , Aug 9, 2018 |  BC Innovations  |  Translation in Brief

Identifying the ubiquitinators

A team at University of Dundee and Newcastle University has developed a mass spectrometry-based screening platform to identify ubiquitin ligases and compounds that modulate them. The approach uses the uptake of ubiquitin by enzymes rather...
21:35 , Aug 3, 2018 |  BC Extra  |  Preclinical News

Mechanism identified behind thalidomide-induced birth defects

Researchers at Dana-Farber Cancer Institute uncovered the mechanistic pathway by which thalidomide and two related analogs cause severe fetal harm, answering a long-held question about the three teratogenic drugs now used as cancer therapies. The...
22:15 , May 11, 2018 |  BC Extra  |  Preclinical News

Inhibiting the ubiquitin ligase RNF5 to treat CF

In a paper published in Cell Chemical Biology , Italian researchers identified a pharmacological inhibitor of ring finger protein 5 (RNF5) that prevented the premature degradation of mutant F508del cystic fibrosis transmembrane conductance regulator (CFTR)...